Quantcast
Last updated on April 19, 2014 at 5:20 EDT

Latest Galeterone Stories

2014-03-27 08:33:33

DUBLIN, Mar. 27, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/djkgl4/therapeutic_class ) has announced the addition of the "Therapeutic Class Overview: Newer Oral Anti Androgens - Expanding Role in the Treatment Paradigm of Prostate Cancer" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) In recent past approval and launch of various newer treatment options like Xtandi (Enzalutamide,...

2014-02-24 12:26:47

DALLAS, February 24, 2014 /PRNewswire/ -- ReportsnReports.com offers "Therapeutic Class Overview : Emergence Of Biogenerics Era In Japan - It's Time to Welcome Antibody Biosimilars of Foreign Origins Soon" and "Therapeutic Class Overview: Newer Oral Anti Androgens - Expanding Role in the treatment Paradigm of Prostate Cancer" research reports in its store. Japan biosimilar market will enter new phase of biosimilars with first 'mab' approval expected in 2014. This...

2013-11-12 23:27:36

Reportbuyer.com just published a new market research report: The Prostate Cancer Therapeutics Market 2013-2023. London (PRWEB) November 12, 2013 Report Details Prostate cancer therapeutics - assess products, developments, and revenue prospects How are the leading segments in the prostate cancer therapeutics market performing? Visiongain's new report shows you their prospects to 2023. There you see results, trends, opportunities, and revenue predictions. Our study lets you assess...

2012-10-01 02:31:07

SAN DIEGO, Oct. 1, 2012 /PRNewswire/ -- Aragon Pharmaceuticals Inc., a leader in developing drugs for hormone driven cancers, announced new data from an ongoing, open-label, multicenter Phase II study of ARN-509, the company's 2nd generation androgen receptor antagonist, demonstrating promising results of ARN-509 in three separate patient populations with castration resistant prostate cancer (CRPC). Data were presented at the European Society for Medical Oncology 2012 Annual Meeting in...

2012-09-05 02:32:26

SEATTLE, Sept. 5, 2012 /PRNewswire/ - Oncothyreon Inc. (Nasdaq: ONTY) today announced that an ongoing Phase 2 trial of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer will be expanded to include an additional group of up to 25 patients whose disease has begun to progress while receiving abiraterone (Zytiga®) and prednisone. PX-866 is Oncothyreon's small molecule compound designed to inhibit the activity of phosphatidylinositol-3-kinase (PI-3K),...